multiple sclerosis - search results

The U.S. FDA has approved TG Therapeutics' BRIUMVI (ublituximab-xiiy) for relapsing forms of multiple sclerosis.

A proteomics study highlights three genes, two novel associations, that appear to contribute to the pathogenesis of multiple sclerosis.

Four new target molecules of potential significance for future personalized treatment of multiple sclerosis (MS) have been identified by researchers at the Karolinska Institute in Sweden.

Data to support the FDA designation was derived from a study at the University of Basel, and University Hospital Basel that employed the company’s Simoa platform to identify and interpret elevated values of serum neurofilament light chain in individual Multiple sclerosis patients.

A new study from the University of Zurich analyzed molecular signatures of circulating immune cell types in identical (monozygotic) twins, where both siblings carry the same genetic and early-life environmental risks, but only one sibling is affected by multiple sclerosis (MS), to investigate the interactions between environmental and genetic factors in this condition.

Web-like DNA structures called neutrophil extracellular traps (NETs) can trigger the onset of autoimmune diseases such as multiple sclerosis (MS), according to research from the Australian National University (ANU).

Large-scale study strengthens link between Epstein-Barr Virus (EBV) infection and multiple sclerosis (MS). Prior EBV infection raises risk of MS 32-fold.

MS patients with high levels of the protein—defined as being more than 80% higher than that of people in the control group (3524 MS patients)—had a 40-70% increased risk of worsening disability due to their condition after one year.

Large-scale, genome-wide analysis of more than 110,000 samples has been completed by a worldwide consortium of scientists.

The MS causing genetic mutation should erase doubts that some forms of the neurological disease are inherited.